S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Adamis Pharmaceuticals Stock Forecast, Price & News

-0.02 (-2.21 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $0.88
50-Day Range
MA: $1.28
52-Week Range
Now: $0.88
Volume5.98 million shs
Average Volume26.63 million shs
Market Capitalization$118.70 million
P/E RatioN/A
Dividend YieldN/A
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Adamis Pharmaceuticals logo


Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar
January 21, 2021 |  finance.yahoo.com
Adamis Soars After Submitting Covid Drug to FDA
January 20, 2021 |  finance.yahoo.com
ADMP Dec 2020 2.500 call
December 19, 2020 |  finance.yahoo.com
Adamis Pharmaceuticals Corp
December 18, 2020 |  bloomberg.com
Why Adamis Pharmaceuticals Stock Is Trading Lower Today
November 16, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ADMP
Year FoundedN/A



Sales & Book Value

Annual Sales$22.11 million
Book Value$0.58 per share


Net Income$-29,310,000.00
Net Margins-188.31%


Market Cap$118.70 million
Next Earnings Date3/29/2021 (Estimated)


Overall MarketRank

1.33 out of 5 stars

Medical Sector

739th out of 1,969 stocks

Pharmaceutical Preparations Industry

356th out of 771 stocks

Analyst Opinion: 3.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.02 (-2.21 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions

Is Adamis Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Adamis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMP, but not buy additional shares or sell existing shares.
View analyst ratings for Adamis Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Adamis Pharmaceuticals?

Wall Street analysts have given Adamis Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Adamis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Adamis Pharmaceuticals?

Adamis Pharmaceuticals saw a decline in short interest in the month of February. As of February 12th, there was short interest totaling 4,130,000 shares, a decline of 18.5% from the January 28th total of 5,070,000 shares. Based on an average trading volume of 18,730,000 shares, the days-to-cover ratio is currently 0.2 days.
View Adamis Pharmaceuticals' Short Interest

When is Adamis Pharmaceuticals' next earnings date?

Adamis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Adamis Pharmaceuticals

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) issued its quarterly earnings results on Saturday, November, 14th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.05. The specialty pharmaceutical company had revenue of $4.30 million for the quarter, compared to the consensus estimate of $8.15 million. Adamis Pharmaceuticals had a negative net margin of 188.31% and a negative trailing twelve-month return on equity of 99.57%.
View Adamis Pharmaceuticals' earnings history

How has Adamis Pharmaceuticals' stock price been impacted by COVID-19?

Adamis Pharmaceuticals' stock was trading at $0.4029 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ADMP shares have increased by 119.5% and is now trading at $0.8845.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ADMP?

3 brokers have issued 1-year price targets for Adamis Pharmaceuticals' shares. Their forecasts range from $1.00 to $1.50. On average, they expect Adamis Pharmaceuticals' share price to reach $1.25 in the next year. This suggests a possible upside of 41.3% from the stock's current price.
View analysts' price targets for Adamis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Adamis Pharmaceuticals' key executives?

Adamis Pharmaceuticals' management team includes the following people:
  • Mr. Richard C. Williams, Independent Chairman & Consultant (Age 77, Pay $128k)
  • Dr. Dennis J. Carlo, Pres, CEO & Director (Age 78, Pay $697.57k)
  • Mr. Robert O. Hopkins, Sr. VP of Fin., CFO & Sec. (Age 61, Pay $455.16k)
  • Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 51)
  • Dr. Ronald B. Moss, Chief Medical Officer (Age 60, Pay $481.36k)
  • Mr. Robert B. Rothermel, Consultant (Age 77, Pay $41.81k)
  • Mr. Howard C. Birndorf, Independent Director & Consultant (Age 70, Pay $47.82k)
  • Ms. Roshawn A. Blunt, Independent Director & Consultant (Age 46, Pay $47.82k)
  • Ms. Karen K. Daniels, VP of Operations (Age 68)
  • Mr. Mark Flather, Sr. Director of Investor Relations & Corp. Communications

Who are some of Adamis Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

Who are Adamis Pharmaceuticals' major shareholders?

Adamis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (0.57%) and Verdence Capital Advisors LLC (0.06%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert B Rothermel, Robert O Hopkins and Ronald B Moss.
View institutional ownership trends for Adamis Pharmaceuticals

Which institutional investors are selling Adamis Pharmaceuticals stock?

ADMP stock was sold by a variety of institutional investors in the last quarter, including Verdence Capital Advisors LLC. Company insiders that have sold Adamis Pharmaceuticals company stock in the last year include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert O Hopkins, and Ronald B Moss.
View insider buying and selling activity for Adamis Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Adamis Pharmaceuticals stock?

ADMP stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP.
View insider buying and selling activity for Adamis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $0.88.

How much money does Adamis Pharmaceuticals make?

Adamis Pharmaceuticals has a market capitalization of $118.70 million and generates $22.11 million in revenue each year. The specialty pharmaceutical company earns $-29,310,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Adamis Pharmaceuticals have?

Adamis Pharmaceuticals employs 131 workers across the globe.

What is Adamis Pharmaceuticals' official website?

The official website for Adamis Pharmaceuticals is www.adamispharmaceuticals.com.

Where are Adamis Pharmaceuticals' headquarters?

Adamis Pharmaceuticals is headquartered at 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]

This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.